The FDA signs off on booster shots of Pfizer’s COVID-19 vaccine for older and at-risk adults; the House of Representatives voted to advance an abortion rights bill; a Gallup poll finds that 18 million US adults cannot afford at least 1 prescription for their household.
The FDA signed off on the targeted use of booster doses of Pfizer’s COVID-19 vaccine in Americans 65 years and older, as well as younger adults with health conditions or jobs that put them at high risk for COVID-19, according to a report from AP News. The ruling represents a scaled back version of the plan that the Biden administration pushed for, which called for nearly all US adults to receive third doses of the vaccine to control the spread of the highly contagious Delta variant. Under the FDA authorization, Americans who have received the Pfizer COVID-19 vaccine will be eligible for a third dose 6 months after receiving their second shot. US regulators will decide at a later time whether boosters for people who have received the Moderna or Johnson & Johnson vaccines are necessary.
The US House of Representatives voted to advance a bill that would protect the right to abortion and annul some restrictions that have been passed by Republican-controlled state governments. A report from Reuters said that the Women’s Health Protection Act is unlikely to succeed in the Senate, where Republican opponents can prevent the bill from reaching the 60-vote threshold to pass most legislation. Many Republicans argue that the bill would expand access to abortion beyond the intent of Roe v Wade, the Supreme Court case that established the right to abortion. The bill was sent to the House in response to the Texas abortion ban at 6 weeks of pregnancy, which is often before a person realizes that they are pregnant, that went into effect in early September.
According to CBC News, a poll from Gallup and West Health has found that about 18 million US adults, or 7% of the population, were unable to pay for at least 1 prescription medication for their household. Additionally, 1 in 10 adults say they’ve skipped a pill in the past year as a means to save money. Low-income households face an even worse situation. Among households that with an annual income of less than $24,000, the proportion of people unable to pay for at least 1 prescription in the past 3 months jumps to 20%. The survey included 5000 adults and was conducted in June 2021. The results highlight how high health care costs and drug prices are affecting households across the country.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
2 Commerce Drive
Cranbury, NJ 08512